Travere Therapeutics Analyst Ratings
BenzingaApr 25 02:36
HC Wainwright & Co. : Travere Therapeutics (TVTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $19.00.
Zhitong FinanceApr 25 02:40
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $19
BenzingaApr 25 02:38
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
BenzingaApr 18 03:00
Travere Therapeutics Analyst Ratings
BenzingaApr 18 01:22
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
BenzingaApr 18 01:23
Travere Therapeutics Analyst Ratings
BenzingaMar 27 18:47
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Maintains $17 Price Target
BenzingaMar 13 21:45
Travere Therapeutics Analyst Ratings
BenzingaMar 13 21:43
Travere Therapeutics Analyst Ratings
BenzingaFeb 16 21:56
Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating
MT NewswiresJan 29 20:29
Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $11
BenzingaJan 19 03:14
Travere Therapeutics Analyst Ratings
BenzingaJan 19 03:13
Stifel Maintains Hold on Travere Therapeutics, Raises Price Target to $10
BenzingaDec 18, 2023 23:54
Travere Therapeutics Analyst Ratings
BenzingaDec 18, 2023 23:53
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $20
BenzingaDec 16, 2023 02:40
Travere Therapeutics Analyst Ratings
BenzingaDec 16, 2023 02:39
Stifel Nicolaus Sticks to Its Hold Rating for Travere Therapeutics (TVTX)
TipRanksDec 5, 2023 20:28
Citigroup Upgrades Travere Therapeutics to Buy, Raises Price Target to $10
BenzingaDec 5, 2023 20:22
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $18 Price Target
BenzingaDec 5, 2023 19:28
No Data
No Data